Pulmonx Corporation (LUNG)

US — Healthcare Sector
Peers: KIDS  OFIX  SGHT  NPCE  CVRX  CCCC  PRLD  STTK  OM 

Automate Your Wheel Strategy on LUNG

With Tiblio's Option Bot, you can configure your own wheel strategy including LUNG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LUNG
  • Rev/Share 2.2528
  • Book/Share 1.7189
  • PB 0.8785
  • Debt/Equity 0.8225
  • CurrentRatio 5.3468
  • ROIC -0.4699

 

  • MktCap 61527366.0
  • FreeCF/Share -0.8524
  • PFCF -1.7958
  • PE -1.0659
  • Debt/Assets 0.3861
  • DivYield 0
  • ROE -0.6976

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LUNG Piper Sandler Overweight Neutral -- $2.5 July 31, 2025
Initiation LUNG D. Boral Capital -- Buy -- $17 March 10, 2025
Downgrade LUNG Citigroup Buy Neutral $17 $7.5 Dec. 11, 2024

News

After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)
LUNG
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Negative

Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)
Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript
LUNG
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call.

Read More
image for news Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript

About Pulmonx Corporation (LUNG)

  • IPO Date 2020-10-01
  • Website https://pulmonx.com
  • Industry Medical - Devices
  • CEO Steven S. Williamson
  • Employees 291
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.